Over the past 13 years, several new agents have been approved to treat patients with metastatic prostate cancer (PC). As a result, clinical guidelines have been updated frequently that support the expanding the role of combination therapy, particularly by introducing chemotherapy earlier to patients with castrate-sensitive progressive disease. Community urologists often treat PC patients many years before the development of progressive disease, and a growing number of urologists have successfully implemented advanced prostate cancer clinics (APCCs) within their practice setting in order to do so. This interactive activity will discuss the benefits of creating an APCC as well as all of the infrastructure requirements and practical considerations for administering chemotherapy in an office setting, as well as the financial ramifications of this investment in time and resources.
Improve your knowledge in the field of urology by taking one of Elsevier's complimentary continuing medical education courses.